• Prospects for the use of nonhormonal therapies in pathological course of menopause
To content

Prospects for the use of nonhormonal therapies in pathological course of menopause

HEALTH OF WOMAN.2015.5(101):110–117; doi 10.15574/HW.2015.101.110

Prospects for the use of nonhormonal therapies in pathological course of menopause

Veropotvelyan P. N., Tamamsheva A. A., Veropotvelyan N. P., Guzhevskaya I. V., Zhuravlova S. A.
«Inter-provincial center of medical genetics and prenatal diagnosis», Krivoy Rog
Clinical hospital № 2, Krivoy Rog

A.A. Bogomolets National Medical University, Kiev

This article presents a number of publications on the pathological course of menopause, outlining the clinic of climacteric syndrome, possible complications when using menopausal hormone therapy.
An alternative non-hormonal method of treatment – lazeromagnitoreflexotherapay in conjunction with the phytohormone klimadinonom is represented.
The proposed method of treatment leads to a decrease in blood pressure, improves blood rheology, has hepatoprotective and gipolipoddynamic action and contributes to the restoration of the hypothalamic-hypophysary relationship in patients with spontaneous menopause, improves ovarian function, and therefore reduces the risk of cardiovascular disease in the pathological course of menopause .

Key words: menopausal hormone therapy (MHT), menopause, lazeromagnitoreflexootherapy, biologically active points (BAP).

REFERENCES

1. Боярский КЮ, Василевская СЕ. 1998. Цитогенетический анализ овоцитов, полученный у женщин старшей возрастной группы в программе ЭКО. Пробл репрод. 2:34–36.

2. Татарчук ТФ, Сольский ЯП. 2003. Эндокринная гинекология (клинические очерки) 1. К.

3. Serrano D, Mariani L, Mora S et al. 2006. Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT. Maturitas 55:69–75. http://dx.doi.org/10.1016/j.maturitas.2006.01.005; PMid:16500052

4. Ovsyannikova TV, Makarov IO, Kulikov ІА. 2013. Clinical efficacy of non-hormonal therapies in perimenopausal women. Obstetrics, Gynecology and Reproduction 7(3):26–9.

5. Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M et al. 2012. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J. Thromb. Haemost. 10(11):2277–86. http://dx.doi.org/10.1111/j.1538-7836.2012.04919.x; PMid:22963114

6. Lowe GD. 2004. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J. Intern. Med. 256:361–74. http://dx.doi.org/10.1111/j.1365-2796.2004.01400.x; PMid:15485471

7. Grodstein F, Stampfer M, Goldhaber S, Manson J, Colditz G, Speizer FE et al. 1996. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 348(9033):983–7.

8. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, Barrett-Connor E, Hulley SB. 2001. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 103(5):638–42. http://dx.doi.org/10.1016/s1062-1458(01)00300-2; http://dx.doi.org/10.1161/01.cir.103.5.638; http://dx.doi.org/10.1097/00006254-200107000-00021

9. Serov VN, Zimovina UV, Blinov DV, Sandakova EA. 2014. Nonhormonal treatments for climacteric syndrome. Obstetrics and Gynecology 11:96–101.

10. Low DA, Humbing KA, Coso J. 2011. Mechanisms of cutaneous vasodilatation during the postmenopausal hot flash. Menopause 18(4):359–65. http://dx.doi.org/10.1097/gme.0b013e3181f7a17a; PMid:21107299 PMCid:PMC3117955

11. Genazzani AR, Bernandi F, Stomati M et al. 1999. Jorn.Menopause Review Gonadal Steroids and Brain Functions. 4(2):10–21.

12. Зимовина УВ. 2007. Синдром психовегетативной дизрегуляции у женщины в периоде ранней постменопаузы и возможности негормональной и гормональной его коррекции. Дис. канд. мед. наук. Пермь:177.

13. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, Chambon P, Mendelsohn ME. 2002. Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ. Res. 90(10):1087–92.

14. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9):888–902. 2013.

15. Makatsariya AD, Bitsadze OV. 2003. Thrombophilia and antithrombotic therapy in obstetric practice. M:904. In Russ.

16. Arnez JG, Dock-Bregeon AC, Moras D. 1999. J molec. Biol. 286;5:1449–1459.

17. Vorobyov AV, Zimovina UV, Kvikviniya IZ. 2014. Hormone replacement therapy and prevention of thrombotic complications. Obstetrics, gynecology and reproduction 8(2):27–33.

18. Schimatschek HF, Rempis R. 2001. Prevalence of hypomagnesemia in an unselected German population of 16,000 individuals. Magnes Res. 14(4):283–90.

19. Groenestege WM, Hoende-rop JG, van den Heuvel L, Knoers N, Bindels RJ. 2006. The epithelial Mg2± channel transient receptor potential melastatin 6 is regulated by dietary Mg2± content and estrogens. J. Am. Soc. Nephrol. 17(4):1035–43.

20. Gromova OA, Limanov OA, Torshin IYu. 2013. Systematic analysis of basic and clinical research indicates the need for sharing of estrogen-containing preparation with preparation of pyridoxine and magnesium. Obstetrics, gynecology and reproduction. 7(3):35–50.

21. Hameed A, Majeed T, Rauf S, Ashraf M, Jalil MA, Nasrullah M et al. 2001. Effect of oral and injectable contraceptives on serum calcium, magnesium and phosphorus in women. J. Ayub. Med. Coll. Abbottabad. 13(3):24–5.

22. Mezhevitinova EA, Prilepskaya CN, Nazarova NM. 2005. Application of Magne B6 to prevention of adverse effects of hormonal contraception. Russian Bulletin of obstetrician-gynecologist 5:61–2.

23. Maier JA, Malpuech-Brugиre C, Zimowska W, Rayssiguier Y, Mazur A. 2004. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim. Biophys. Acta. 1689(1):13–21.

24. Zhang A, Cheng TP, Altura BT, Altura BM. 1993. Mg2± and caffeine-induced intracellular Ca2± release in human vascular endothelial cells. Br. J. Pharmacol. 109:291–2. http://dx.doi.org/10.1111/j.1476-5381.1993.tb13568.x; PMid:8358532 PMCid:PMC2175709

25. Dickens BF, Weglicki WB, Li YS, Mak IT. 1992. Magnesium deficiency in vitro enhances free radical-induced intracellular oxidation and cytotoxicity in endothelial cells. FEBS Lett. 311(3):187–91.

26. Killilea D, Maier JA. 2008. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnes Res. 21:77–82.

27. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD et al. 1999. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am. J. Cardiol. 84(2):152–6. http://dx.doi.org/10.1016/S0002-9149(99)00225-8

28. Van Laecke S, Nagler EV, Vanholder R. 2012. Thrombotic microangiopathy: a role for magnesium? Thromb. Haemost. 107(3):399-408. http://dx.doi.org/10.1160/TH11-08-0593.

29. Bogolyubov VM, Ponomarenko GN. 1998. General physiotherapy. SPb.

30. Gurlenov AM, Bagel GE. 1989. Physiotherapy, balneology and Nervous Diseases: Scient. edition. Mn:57–59.